Due: December 11, 2025
The United States Government (USG) has a requirement to expand domestic commercial biopharmaceutical manufacturing capabilities. To meet this need, the USG is initiating an effort to onshore the manufacturing of novel Vesicular Stomatitis Virus (VSV) Delta G based vaccine candidates, expressed in Vero cells, for protection against viral hemorrhagic fever viruses such as Marburg and Ebola Sudan. At present, there is no domestic manufacturing capability for viral hemorrhagic fever vaccines; therefore, it is in the USG’s interest to establish this capability to prepare for and respond to potential viral outbreaks. This effort will involve the technology transfer of the current candidate vaccine production processes (inclusive of bulk drug substance and drug product (formulation, fill/finish)) from their current manufacturing sites, located outside the U.S., to one or more domestic Contract Development and Manufacturing Organizations (CDMOs) located within the US.
This opportunity requires membership in the BioMap Consortium. This Consortium releases numerous opportunities throughout the year, so even if this one may not be right for you, we strongly encourage you to join the consortium, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.